title: Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of 2 regimens of tiagabine as add-on therapy for patients with complex partial seizures (CPSs) that are refractory to other treatment.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled, add-on, parallel-group trial with an 8-week baseline period, 12-week experimental period (4 weeks of dose titration and 8 weeks of fixed-dose therapy), and 4-week termination period.
  
  
  METHODS
  Twenty-six centers throughout the United States.
  
  
  METHODS
  Three hundred fifty-one patients were enrolled, 318 were entered in the double-blind period, and 271 completed the study.
  
  
  METHODS
  Tiagabine, 16 mg 2 times per day (106 patients); tiagabine, 8 mg 4 times daily (105 patients); and placebo (107 patients). The doses of tiagabine were titrated in 3 steps to the fixed dose.
  
  
  METHODS
  The median change in the 4-week rate of CPSs from baseline to experimental period.
  
  
  RESULTS
  The median change from baseline was -1.6 CPSs per 4 weeks in the group of patients who were given tiagabine 2 times per day, and it was -1.2 CPSs in the group of patients who were given tiagabine 4 time per day (P = .06 and P = .02, respectively, compared with placebo). The 4-week seizure frequency was reduced by 50% or more in 31% of the patients who were given tiagabine 2 times per day and in 27% of the patients who were given tiagabine 4 times per day vs 10% of the placebo-treated patients (P < or = .001 for each tiagabine-treated group compared with the placebo group). The most frequent adverse events involved the central nervous system and occurred in comparable proportions in the 3 treatment groups. Similar proportions of patients discontinued the study prematurely for adverse events.
  
  
  CONCLUSIONS
  Tiagabine administered 2 and 4 times daily as add-on pharmacotherapy was effective in reducing CPSs in patients with epilepsy whose conditions were refractory to treatment with other antiepileptic agents, and it was well tolerated.
authors.affiliation: Department of Neurology, University of Medicine and Dentistry of New Jersey, New Brunswick 08901-2160, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Sachdeo
authors.forename: R F
authors.initials: RF
authors.lastname: Leroy
authors.forename: G L
authors.initials: GL
authors.lastname: Krauss
authors.forename: M E
authors.initials: ME
authors.lastname: Drake
authors.forename: P M
authors.initials: PM
authors.lastname: Green
authors.forename: I E
authors.initials: IE
authors.lastname: Leppik
authors.forename: V S
authors.initials: VS
authors.lastname: Shu
authors.forename: G L
authors.initials: GL
authors.lastname: Ringham
authors.forename: K W
authors.initials: KW
authors.lastname: Sommerville
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D017029:Epilepsy, Complex Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009557:Nipecotic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019233:Retreatment; D000078308:Tiagabine; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D009557:Nipecotic Acids; D000078308:Tiagabine